Vesalius is developing a catheter-based device able to treat a major and very common heart valve disease, without surgery. We are currently at preclinical stage.

The disease is called Degenerative Mitral Regurgitation, an abnormal leak inside of the heart affecting 5% of the population. Current gold standard treatment is open-heart surgery. It is effective but unfortunately unsafe for 60% of patients: this is the unmet clinical need.

In Parallel, currently emerging catheter-based solutions are ineffective for 60%-75% of patients.

Therefore, this space is begging for a safe and effective solution; and this is what Vesalius is developing:

– A safe solution since it is catheter-based (transfemoral/transseptal, an already established delivery technique).

– An effective solution that can treat 95% of patients. Our superior and unique concept is based on current surgical principles, using proven surgical material and able to treat any affected/diseased area of the valve. We are delivering the surgery effects but with a catheter.